Cogent Biosciences (COGT) Operating Expenses (2017 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Cogent Biosciences was $389.09 million, up 29.8% year-over-year; for FY2025, it was $333.36 million, up 20.8% from FY2024.

• Annual Operating Expenses has increased for four consecutive years, with a five-year compound annual growth rate of 29.9% (FY2020 to FY2025).
• In prior years, Cogent Biosciences' Operating Expenses was $275.94 million in FY2024 (+32.6%), $208.13 million in FY2023 (+40.8%), $147.84 million in FY2022 (+95.7%) and $75.55 million in FY2021 (-16.1%).
• Quarterly Operating Expenses has run from a low of $19.82 million in Q3 2021 to a high of $103.61 million in Q1 2026 over five years.
• On a year-over-year basis, Operating Expenses has increased in each of the last 19 quarters, with growth averaging 26.3% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q1 2022, with growth of 145.5%; the weakest was Q3 2021, with a decline of 65.5%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $103.61 million (Q1 2026), $99.49 million (Q4 2025) and $83.36 million (Q3 2025).